The trial accomplished both of those its Major endpoints, with semaglutide two.four mg demonstrating statistically sizeable and remarkable advancements in liver fibrosis without any worsening of steatohepatitis, together with resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH compared to placebo.onePancreatit